43 patents
Utility
Methods of Treatment of Liver Failure
4 Jan 24
The invention relates to the treatment or prevention of liver failure.
Philippe DELATAILLE, Robert WALCZAK, Corinne FOUCART, Vanessa LEGRY, Nicolas STANKOVIC VALENTIN, Simon DEBAECKER, Rémy HANF
Filed: 16 Nov 21
Utility
Methods of Diagnostic of Liver Fibrosis
4 Jan 24
The invention relates to a method for the identification of NAFLD patients likely to develop advanced liver fibrosis within 52 weeks.
SUNEIL HOSMANE, JÉRÉMY MAGNANENSI, YACINE HAJJI
Filed: 29 Oct 21
Utility
Methods of treatment of cholestatic diseases
2 Jan 24
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Remy Hanf
Filed: 20 Jun 23
Utility
Methods of Treatment of Cholestatic Diseases
26 Oct 23
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Remy Hanf
Filed: 20 Jun 23
Utility
Methods of Treatment of Cholestatic Diseases
19 Oct 23
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Remy Hanf
Filed: 20 Jun 23
Utility
In Vitro Model of Liver Steatohepatitis
12 Oct 23
The present invention relates to methods for preparing in vitro models of nonalcoholic steatohepatitis.
GUILLAUME VIDAL, ROBERT WALCZAK
Filed: 23 Jun 21
Utility
Compositions and Methods for the Treatment of Primary Biliary Cholangitis
28 Sep 23
The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
Pascal Birman, Alice Roudot, David Magrez, Benoit Noel
Filed: 25 Aug 21
Utility
Method for Nash Risk Assessment
21 Sep 23
The present invention relates to a new assay to diagnose nonalcoholic steatohepatitis (NASH), NASH progression and NASH fibrosis stage.
ZOUHER MAJD, PIERRE CHAUMAT
Filed: 2 Aug 21
Utility
Polymorphs of Elafibranor
30 Mar 23
The present invention relates to novel crystalline forms of elafibranor.
Karine BERTRAND, Jean-François DELHOMEL, Alice ROUDOT
Filed: 4 Feb 21
Utility
Pharmaceutical compositions for combination therapy
28 Feb 23
The present invention relates to a combination of active ingredients for use in the treatment of diseases.
Emeline Descamps, Robert Walczak, Carole Belanger, Benoît Noel
Filed: 23 Feb 18
Utility
Treatment of Primary Biliary Cholangitis with Elafibranor
16 Feb 23
The invention relates to a pharmaceutical composition comprising elafibranor, GFT1007 or a pharmaceutically acceptable salt of elafibranor or of GFT1007, for use to treat primary biliary cholangitis (PBC) without provoking and/or worsening at least one adverse event associated to PBC.
Stephanie Petit, Julie Mouton, Julie Dietrich, Omar Olhaye, Pascal Birman
Filed: 4 Feb 21
Utility
Phosphate Derivatives of Rorgamma Modulators and Uses Thereof
9 Feb 23
The present invention relates to phosphate derivatives of formula (I), and their therapeutic uses, preferably for treating a respiratory disease.
JEAN-FRANÇOIS DELHOMEL, ROBERT WALCZAK, PEGGY PARROCHE, ANNE-MARIE SAVERET
Filed: 17 Dec 20
Utility
Methods for Diagnosing and Evaluating Non-alcoholic Steatohepatitis
29 Dec 22
The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200.
Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
Filed: 24 Jun 22
Utility
Combination Therapy Having Antioxydant Properties
22 Dec 22
The present invention relates to novel uses of nitazoxanide, or analogues thereof.
NICOLAS STANKOVIC-VALENTIN, PEGGY PARROCHE, CORINNE FOUCART, ROBERT WALCZAK
Filed: 27 Oct 20
Utility
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
6 Dec 22
The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.
Remy Hanf, Genevieve Cordonnier, John Brozek
Filed: 14 Sep 18
Utility
Combination Therapy Comprising Compounds of Formula (I) and GLP-1 Receptor Agonists
17 Nov 22
The present invention relates to a combination therapy comprising a PPAR agonist and a GLP-1 receptor agonist.
ROBERT WALCZAK, VANESSA LEGRY, EMELINE DESCAMPS
Filed: 9 Apr 20
Utility
Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor
1 Nov 22
The present invention relates to a combination product and its use in therapy.
Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak, Isabelle Delbaere
Filed: 18 Apr 18
Utility
Quantitative Detection of Micro-rnas
27 Oct 22
The present invention is directed to novel compositions and methods useful for the quantitative detection of microRNAs.
ZOUHER MAJD
Filed: 22 Apr 21
Utility
Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
25 Oct 22
The present invention relates to a combination product and its use in therapy.
Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak
Filed: 18 Apr 18
Utility
Methods of Treatment for Cholestatic and Fibrotic Diseases
13 Oct 22
The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.
Robert WALCZAK, Corinne FOUCART, Philippe DELATAILLE
Filed: 28 Jun 22